Google
HUMAW — HUMACYTE INC
HUMAW FAQ
What is HUMAW's ROE?
HUMACYTE INC reports a Return on Equity (ROE) of -839.56%.
What is HUMAW's dividend yield?
HUMACYTE INC offers a dividend yield of 0.00%.
What is HUMAW's Deepscope Quality Score?
Deepscope rates HUMAW's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HUMAW?
Deepscope's AI Timing Score for HUMAW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
|
USD 0.02
Price
-0.02
(-48.99%)
Day Change
|
|
|---|
HUMAW, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.02 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
668.606715000000
|
| Average 1W Daily Value |
513.431300000000
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2525 East North Carolina Highway 54, Durham, NC, United States, 27713
Phone: 919 313 9633
Website: https://www.humacyte.com
Employees: 184
Sector: -
Description: Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
ME vs SECTOR
Click a bubble to view stock details · Bubble size represents market capitalization share
